Elekta Versa HD Linear Accelerator Radiation Therapy

March 3, 2013 — During a live global event, Elekta announced the launch of Versa HD, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.

Versatility to deliver better treatments to more patients

Versa HD gives clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. As an integrated treatment system, Versa HD offers the versatility to address today's growing cancer management challenges.

"The well-being of increasing numbers of cancer patients worldwide inspired us to create Versa HD," says Elekta's President and CEO, Tomas Puusepp. "We strived to incorporate technologies that would provide an immediate impact to patient health and quality of life. As the pioneers of many of today's most advanced therapies, we are proud to introduce Versa HD as yet another market-leading innovation. Versa HD truly reflects the best thinking of Elekta's technical experts and our clinical partners."

Integrated with Elekta's recently-launched Agility 160-leaf multileaf collimator (MLC), Versa HD provides highly conformal beam shaping — a critical requirement for maximizing the dose to the target while also preserving surrounding healthy tissues. Importantly, this high targeting accuracy is available over a large field-of-view, permitting delivery of high-definition (HD) beams to a wide spectrum of complex targets. Historically, high-definition beam shaping often was mechanically limited to only small target therapies. Versa HD with Agility overcomes this challenge, now empowering clinicians to deliver extremely precise beam contouring for both small and large targets.

Unprecedented combination of High Dose Rate delivery and rapid MLC leaf speed

Capable of delivering radiation doses three times faster than previous generation Elekta linear accelerators, Versa HD harnesses the ultra-fast leaf speeds of Agility MLC. With this groundbreaking combination, clinicians can now, for the first time, take full advantage of higher dose rate delivery, potentially enabling even greater capabilities for sophisticated therapies, including stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT) and volumetric modulated arc therapy (VMAT).

"Historically, MLC leaf speed has been a limiting factor in adopting high dose rate delivery. The leaves were often incapable of moving fast enough to provide advanced modulations with the increased dose rate," says Elekta's Kevin Brown, global vice president scientific research. "With Versa HD, clinicians can now take full advantage of high dose rate delivery, and provide highly exquisite conformance with much greater efficiency."

To reduce environmental impact and operating costs, Versa HD consumes up to 30 percent less energy than other delivery systems. Versa HD also debuts with modern ergonomics, including a more patient-friendly, softer and sleeker exterior, new user controls and ambient lighting effects.

Versa HD is not available for sale or distribution in all markets. Elements of Versa HD are pending FDA 510(k) clearance.

For more information: www.VersaHD.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
Subscribe Now